Disease activity and disability but probably not glucocorticoid treatment predicts loss in bone mineral density in women with early rheumatoid arthritis

References

• Deodhar A. A., Woolf A. D. Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Br J Rheumatol 1996; 35: 309–22
   PubMedGoogle Scholar
• Hansen M., Florescu A., Stoltenberg M., Podenphant J., Pedersen‐Zbinden B., Horslev‐Petersen K., et al. Bone loss in rheumatoid arthritis. Influence of disease activity, duration of the disease, functional capacity, and corticosteroid treatment. Scand J Rheumatol 1996; 25: 367–76
   PubMed Web of Science ®Google Scholar
• Kennedy A. C., Smith D. A., Anton H. C., Buchanan W. W. Generalised and localised bone loss in patients with rheumatoid arthritis. Scand J Rheumatol 1975; 4: 209–15
   PubMed Web of Science ®Google Scholar
• Lane N. E., Pressman A. R., Star V. L., Cummings S. R., Nevitt M. C. Rheumatoid arthritis and bone mineral density in elderly women. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1995; 10: 257–63
   PubMed Web of Science ®Google Scholar
• Haugeberg G., Uhlig T., Falch J. A., Halse J. I., Kvien T. K. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum 2000; 43: 522–30
   PubMed Web of Science ®Google Scholar
• Keller C., Hafstrom I., Svensson B. Bone mineral density in women and men with early rheumatoid arthritis. Scand J Rheumatol 2001; 30: 213–20
   PubMedGoogle Scholar
• Aman S., Hakala M., Silvennoinen J., Manelius J., Risteli L., Risteli J. Low incidence of osteoporosis in a two year follow‐up of early community based patients with rheumatoid arthritis. Scand J Rheumatol 1998; 27: 188–93
   PubMedGoogle Scholar
• Kroot E. J., Nieuwenhuizen M. G., de Waal Malefijt M. C., van Riel P. L., Pasker‐de Jong P. C., Laan R. F. Change in bone mineral density in patients with rheumatoid arthritis during the first decade of the disease. Arthritis Rheum 2001; 44: 1254–60
   PubMed Web of Science ®Google Scholar
• Sambrook P. N., Eisman J. A., Champion G. D., Yeates M. G., Pocock N. A., Eberl S. Determinants of axial bone loss in rheumatoid arthritis. Arthritis Rheum 1987; 30: 721–8
   PubMed Web of Science ®Google Scholar
• Hall G. M., Spector T. D., Griffin A. J., Jawad A. S., Hall M. L., Doyle D. V. The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. Arthritis Rheum 1993; 36: 1510–16
   PubMed Web of Science ®Google Scholar
• Haugeberg G., Orstavik R. E., Uhlig T., Falch J. A., Halse J. I., Kvien T. K. Bone loss in patients with rheumatoid arthritis: results from a population‐based cohort of 366 patients followed up for two years. Arthritis Rheum 2002; 46: 1720–8
   PubMed Web of Science ®Google Scholar
• Sinigaglia L., Nervetti A., Mela Q., Bianchi G., Del Puente A., Di Munno O., et al. A multicenter cross‐sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol 2000; 27: 2582–9
   PubMed Web of Science ®Google Scholar
• D'Elia H. F., Larsen A., Mattsson L. A., Waltbrand E., Kvist G., Mellstrom D., et al. Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. J Rheumatol 2003; 30: 1456–63
   PubMed Web of Science ®Google Scholar
• Romas E. Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates. Best Pract Res Clin Rheumatol 2005; 19: 1065–79
   PubMedGoogle Scholar
• Kobayashi A., Hirano F., Makino I. The inhibitory effect of bisphosphonates on glucocorticoid‐induced RANKL expression in human cells. Scand J Rheumatol 2005; 34: 480–4
   PubMed Web of Science ®Google Scholar
• Gough A. K., Lilley J., Eyre S., Holder R. L., Emery P. Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994; 344: 23–7
   PubMed Web of Science ®Google Scholar
• Habib G. S., Haj S. Bone mineral density in patients with early rheumatoid arthritis treated with corticosteroids. Clin Rheumatol 2005; 24: 129–33
   PubMedGoogle Scholar
• Gerdhem P., Akesson K., Obrant K. J. Effect of previous and present physical activity on bone mass in elderly women. Osteoporos Int 2003; 14: 208–12
   PubMedGoogle Scholar
• Prevoo M. L., van 't Hof M. A., Kuper H. H., van Leeuwen M. A., van de Putte L. B., van Riel P. L. Modified disease activity scores that include twenty‐eight‐joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44–8
   PubMed Web of Science ®Google Scholar
• Ekdahl C., Eberhardt K., Andersson S. I., Svensson B. Assessing disability in patients with rheumatoid arthritis. Use of a Swedish version of the Stanford Health Assessment Questionnaire. Scand J Rheumatol 1988; 17: 263–71
   PubMed Web of Science ®Google Scholar
• Nordenskiold U. M., Grimby G. Grip force in patients with rheumatoid arthritis and fibromyalgia and in healthy subjects. A study with the Grippit instrument. Scand J Rheumatol 1993; 22: 14–19
   PubMed Web of Science ®Google Scholar
• Karlsson M. K., Gardsell P., Johnell O., Nilsson B. E., Akesson K., Obrant K. J. Bone mineral normative data in Malmo, Sweden. Comparison with reference data and hip fracture incidence in other ethnic groups. Acta Orthop Scand 1993; 64: 168–72
   PubMed Web of Science ®Google Scholar
• Kanis J. A., Melton L. J 3rd., Christiansen C., Johnston C. C., Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994; 9: 1137–41
   PubMed Web of Science ®Google Scholar
• Lodder M. C., de Jong Z., Kostense P. J., Molenaar E. T., Staal K., Voskuyl A. E., et al. Bone mineral density in patients with rheumatoid arthritis: relation between disease severity and low bone mineral density. Ann Rheum Dis 2004; 63: 1576–80
   PubMed Web of Science ®Google Scholar
• Cortet B., Guyot M. H., Solau E., Pigny P., Dumoulin F., Flipo R. M., et al. Factors influencing bone loss in rheumatoid arthritis: a longitudinal study. Clin Exp Rheumatol 2000; 18: 683–90
   PubMed Web of Science ®Google Scholar
• van Everdingen A. A., Siewertsz van Reesema D. R., Jacobs J. W., Bijlsma J. W. Low‐dose glucocorticoids in early rheumatoid arthritis: discordant effects on bone mineral density and fractures?. Clin Exp Rheumatol 2003; 21: 155–60
   PubMed Web of Science ®Google Scholar
• Boers M., Verhoeven A. C., Markusse H. M., van de Laar M. A., Westhovens R., van Denderen J. C., et al. Randomised comparison of combined step‐down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309–18
   PubMed Web of Science ®Google Scholar
• Capell H. A., Madhok R., Hunter J. A., Porter D., Morrison E., Larkin J., et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis 2004; 63: 797–803
   PubMed Web of Science ®Google Scholar
• Svensson B., Boonen A., Albertsson K., van der Heijde D., Keller C., Hafstrom I. Low‐dose prednisolone in addition to the initial disease‐modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two‐year randomized trial. Arthritis Rheum 2005; 52: 3360–70
   PubMed Web of Science ®Google Scholar
• Yilmaz L., Ozoran K., Gunduz O. H., Ucan H., Yucel M. Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids. Rheumatol Int 2001; 20: 65–9
   PubMedGoogle Scholar
• Jackson R. D., LaCroix A. Z., Gass M., Wallace R. B., Robbins J., Lewis C. E., et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354: 669–83
   PubMed Web of Science ®Google Scholar